logo
Worm-Inspired Treatments Inch Toward the Clinic

Worm-Inspired Treatments Inch Toward the Clinic

Medscape6 hours ago

The experiment was a striking attempt to investigate weight control. For 6 weeks, a group of mice gorged on lard-enriched mouse chow, then scientists infected the mice with worms. The worms wriggled beneath the animals' skin, migrated to blood vessels that surround the intestines, and started laying eggs.
Bruno Guigas, a molecular biologist at the Leiden University Center for Infectious Diseases in the Netherlands, led this study some years back and the results, he says, were 'quite spectacular.' The mice lost fat and gained less weight overall than mice not exposed to worms. Within a month or so, he recalls, the scientists barely needed their scale to see that the worm-infested mice were leaner than their worm-free counterparts. Infection with worms, it seems, reversed obesity, the researchers reported in 2015.
While it's true that worms gobble up food their hosts might otherwise digest, that doesn't seem to be the only mechanism at work here. There's also some intricate biology within the emerging scientific field of immunometabolism.
Over the past couple of decades, researchers have recognized that the immune system doesn't just fight infection. It's also intertwined with organs like the liver, the pancreas and fat tissue, and implicated in the progression of obesity and type 2 diabetes. These and other metabolic disorders generate a troublesome immune response — inflammation — that worsens metabolism still further. Metabolic disease, in other words, is inflammatory disease.
Scientists have also observed a metabolic influence of worms in people who became naturally infected with the parasites or were purposely seeded with worms in clinical trials. While the physiology isn't fully understood, the worms seem to dampen inflammation, as discussed in the 2024 Annual Review of Nutrition .
'We're never going to cure or treat metabolic disease with worm infections,' says Guigas. They cause unpleasant side effects like nausea, and it would be impractical to dose millions of people with parasites. But worms can be valuable tools for scientists to understand the feedback between inflammation and metabolism. The findings could inspire more traditional, less ick-inducing treatments.
The Worms' Good Turns
The worms we're talking about are helminths such as flukes and roundworms. While they've largely been eliminated from developed nations, an estimated 1.5 billion people worldwide carry them. They can be dangerous in high numbers, and cause symptoms such as diarrhea and malnutrition in those at high risk, including children and immunocompromised individuals, and during pregnancy.
But for most people, infection with a few worms is pretty benign. 'Throughout human evolution, I think, there's been this nice sort of truce,' says Paul Giacomin, an immunologist at James Cook University in Cairns, Australia. As part of that detente, he says, helminths evolved molecules that tell the human immune system, 'I'm not here, don't worry about me.' In turn, people might have evolved to depend a bit on worms to temper inflammation.
Today, metabolic disease is a massive global problem, with obesity affecting an estimated 890 million people. Another 580 million have type 2 diabetes, which arises when the hormone insulin, which controls blood sugar levels, is in short supply or the body's cells become insensitive to it.
Links between metabolic disease and worm infection emerged from research on human populations. Studies in Australia, Turkey, Brazil, China, India and Indonesia showed that people with metabolic conditions such as diabetes were less likely to have helminth infections, and vice versa. 'This observation is quite strong,' says Ari Molofsky, an immunologist at the University of California, San Francisco.
Going a step further, scientists observed what happened when they provided deworming treatments.' The overwhelming majority of the studies showed that deworming worsens your metabolic health,' says Giacomin.
Scientists looked to lab mice for additional clues. Molofsky and colleagues, in 2011, reported that when they infected mice on high-fat food with the gut worm Nippostrongylus brasiliensis , the infection improved blood sugar control. Similarly, in Guigas' study, published in 2015, the worms — blood flukes called Schistosoma mansoni — improved not just weight, but also blood sugar processing. And the worms needn't be alive: Even molecules collected from crushed worm eggs improved metabolism.
The going hypothesis is that metabolic problems kick off a vicious immunometabolic cycle. First, Guigas says, damaged cells in metabolic organs cry for help, releasing molecular signals that call in immune cells. When the immune cells arrive, they morph into forms that promote a type of inflammation called Th1. Th1 responses are good at combating viruses, but they're the wrong choice here. Th1 can aggravate metabolic problems by impairing insulin manufacture, altering insulin signaling and amplifying insulin resistance.
Thus, instead of helping, the immune cells cause further stress in the metabolic tissues. So the tissues call in more immune cells — and the cycle repeats.
Worms seem to break the cycle. In great part, that's probably because their 'I'm not here' message causes a different kind of immune response, Th2, that dampens the Th1 reaction and re-normalizes the system. Other mechanisms might also be at work: Worms might reduce appetite; it's known they can alter gut microbes; and Guigas suspects they can also manipulate creatures' metabolisms via non-immune pathways.
'The parasitic worms are real masters at controlling inflammation,' says Giacomin, who coauthored an article on helminths and immunity in the 2021 Annual Review of Immunology . Thus, scientists interested in controlling immunometabolic disease might take cues from these wriggly little metabolic masterminds. In fact, researchers have already tested helminths to control inflammation in autoimmune conditions such as inflammatory bowel disease.
The accumulating evidence linking worms to metabolic benefits in animals and people inspired Giacomin and colleagues to conduct a trial of their own. Commencing in 2018, they decided to try the hookworm Necator americanus in 27 obese people who had insulin resistance, putting them at risk for type 2 diabetes. The researchers applied worm larvae in patches on the subjects' arms; after passing through the skin, the worms would travel through the blood stream, to the lungs and then to the small intestine. An additional 13 participants were assigned to placebo patches with Tabasco sauce to mimic the itch of entering worms.
N americanus is a common cause of hookworm infections across much of the world. While most cases are asymptomatic, the time when the worms are attaching to the intestinal wall can cause symptoms like nausea and low iron levels, especially if there are a lot of worms. So the main goal was to determine if the treatment was safe, trying doses of 20 or 40 worms. Many subjects suffered short-term unpleasantness such as bloating or diarrhea as they adjusted to their new intestinal tagalongs, but overall, most did fine.
After 12 months, the people who got hookworms had lower insulin resistance and reduced fasting blood sugar levels. After two years, those who received 20 worms had lost an average of 11 pounds — though not all individuals lost weight, and some gained.
'It was quite convincing that the worms were having some sort of beneficial effect,' says Giacomin. The subjects were convinced too: When the study was over, the researchers offered deworming, but most participants elected to keep their worms.
Giacomin and Guigas hope to identify worm components or invent worm-inspired molecules to produce similar effects without whole parasites. Giacomin cofounded a company, Macrobiome Therapeutics in Cairns, to develop hookworm molecules into treatments. Such medications might be based on the wriggly parasites, but they'd be an easier pill to swallow.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Spironolactone Offers No CV Benefit in Dialysis Patients
Spironolactone Offers No CV Benefit in Dialysis Patients

Medscape

timean hour ago

  • Medscape

Spironolactone Offers No CV Benefit in Dialysis Patients

VIENNA — Spironolactone, a mineralocorticoid receptor antagonist (MRA), does not reduce the rates of cardiovascular (CV) death or heart failure in patients undergoing maintenance dialysis, according to ACHIEVE trial results. In addition, the relatively high rates of hyperkalemia associated with the drug — despite a run-in period — limit its use, said lead investigator Michael Walsh, MD, PhD, Renal Research Program, Population Health Research Institute, Hamilton, Ontario, Canada, who presented the results at the 62nd European Renal Association Congress on June 6. He added: 'Cardiovascular mortality remains very high' in these patients, at the 'somewhat astounding' rate of 11% per year in the current trial. The ACHIEVE Trial Previous trials have suggested that MRAs are perhaps the 'most promising therapies' in this space, Walsh noted. He and his colleagues undertook the Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE) trial to evaluate the efficacy and safety of spironolactone. The study included patients (age, ≥ 45 y or ≥ 18 y with history of diabetes) with kidney failure receiving maintenance dialysis who were at risk of CV death. All patients underwent an active run-in where they were prescribed open-label spironolactone 25 mg/day for at least 7 weeks with no dosing adjustments followed by a final eligibility assessment to ensure they were ≥ 80% adherent to the medication and that their serum potassium levels did not exceed 6.0 mmol/L. After the run-in period, 2538 of the originally selected 3565 patients were randomized to either spironolactone 25 mg/day or matching placebo. Follow-up was at 3 months, 6 months, and then every 6 months after, assessing for outcomes, safety, drug adherence, and drug resupply. Unlike the run-in period, clinicians could reduce the dose to 25 mg/three times a week if appropriate. The average age of the patients was approximately 62 years, roughly 37% were female, and the median time that the patients had been receiving dialysis was 2 years. The primary cause of kidney failure was diabetes, in just over 40% of patients, followed by hypertension/ischemia in slightly over 25%. The trial was stopped early by the external safety and event monitoring committee for futility, meaning it did not reach the target number events, even after the target had been revised downward due to better-than-expected adherence. Walsh stated that the trial did not reach its primary outcome, with no significant difference in rates of CV death or heart failure hospitalization between the spironolactone and placebo groups at a hazard ratio (HR) of 0.92 ( P = .35). There was also no significant difference between the two treatments when stratifying the patients by sex, previous heart failure, previous coronary artery disease, and the length of time they had been receiving dialysis. Further analysis indicated there was no benefit from spironolactone over placebo when looking at cardiac and vascular deaths separately and when considering first and total heart failure hospitalizations individually. However, spironolactone was associated with an increased risk of hyperkalemia, with 123 events in the spironolactone-treated group vs 80 in the placebo group (HR, 1.54; 95% CI, 1.07-2.22). Walsh noted that, despite the strengths of its large size and the high rates of adherence, the trial is limited by having a low statistical power due to being stopped early, the use of a composite primary outcome, and the challenge in defining the patients most likely to benefit from the intervention. Important Clinical Question Session co-Chair Ronald T. Gansevoort, MD, PhD, professor of medicine and a nephrologist at the Department of Nephrology, University Medical Center Groningen, Netherlands, told Medscape Medical News that the study addressed an 'important clinical question,' and it is 'a pity that it didn't work out.' He noted there have been numerous studies of CV disease in patients with chronic kidney disease who are not on dialysis, but 'there have been so few trials in dialysis patients,' and there consequently remains a lot to learn in this space. As to what the current findings mean for MRAs in general in preventing CV outcomes, Gansevoort said he is 'not sure, because there are drug-specific differences between the first, second, and third generation, and we cannot extrapolate the findings with the first generation to the third.' 'Whether there ever will be a trial with the third generation in dialysis patients, I doubt, because industry will not want to fund it,' he continued, and so it will 'remain an important question.' Christoph Wanner, MD, PhD, professor of medicine and head of the Division of Nephrology, University of Würzburg, Germany, noted that even if the number of patients in the trial were increased to 4000 or 5000 it would still not 'resolve the issue.' 'I think it's the end for MRAs in dialysis,' he told Medscape Medical News , and 'we have to think about what's going wrong in dialysis patients.' 'We started with statins. They didn't work. Hemodialysis/ hemodiafiltration does work, but drugs do not work. Why is this the case? What's going on? Did we design the right trials?' Wanner continued, 'I think this is still a [relevant research] question, but at the moment, with the ACHIEVE trial, the story of MRAs in dialysis is coming to an end.' 'Everyone who deals with dialysis patients realizes there is an excess of mortality, despite advancements in the technology of dialysis over the last 50 years,' noted Walsh at the start of his presentation. He continued that there have been reductions in deaths from atheromatous CV disease among patients receiving dialysis for kidney failure, but 'importantly, the other kinds of reasons, including non-atheromatous cardiovascular disease, remain extremely high,' accounting for approximately 40% of all deaths in these patients. 'Trying to understand why there is such a high risk of cardiovascular death has been challenging,' Walsh added. ACHIEVE was funded by grants from the Canadian Institutes of Health Research (Canada), the Medical Research Future Fund (Australia), the Health Research Council (New Zealand), the British Heart Foundation (United Kingdom), the Population Health Research Institute (Canada), St. Joseph's Healthcare Hamilton Division of Nephrology (Canada), Accelerating Clinical Trials (Canada), the CanSOLVE CKD Network (Canada), and the Department of Medicine, Dalhousie University (Canada). No relevant financial relationships declared.

Danny Boyle Reveals ‘Sunshine' Was Once Planned as a Trilogy
Danny Boyle Reveals ‘Sunshine' Was Once Planned as a Trilogy

Gizmodo

time2 hours ago

  • Gizmodo

Danny Boyle Reveals ‘Sunshine' Was Once Planned as a Trilogy

Director Danny Boyle and screenwriter Alex Garland's zombie re-team 28 Years Later opens in a few weeks; there's already a sequel on the way, and a third film will follow if the first two excite audiences. But in a new interview, Boyle shared that 2007's Sunshine, which he made after 28 Days Later and just before his Oscar-winning Slumdog Millionaire, could have sparked another sci-fi franchise—if only it had been a bigger hit. Sunshine has gained a cult following across the past two decades, not least because of its cast of future Oscar winners and blockbuster breakouts: Cillian Murphy, Chris Evans, Rose Byrne, Michelle Yeoh, Cliff Curtis, Mark Strong, Hiroyuki Sanada, Troy Garity, and Benedict Wong. But its tale of an international crew sent on mission to re-ignite the dying sun—dangerous enough even without a sun-crazed saboteur wreaking havoc—failed to draw crowds at the time. Speaking to Collider, Boyle reveals what might have been, without giving too many specifics, of course. 'Originally, when we were doing it, Alex wrote two other parts. It was supposed to be a trilogy,' the director said. He clarified that Garland didn't write two other scripts; instead, he had an outline for where the story would go. 'It was a planetary trilogy. It was to do with the sun itself, with two other stories,' Boyle teased. 'What's interesting is Alex has a natural instinct as a storyteller to want to tell these expanding stories, and that is why 28 Years Later wound up as a trilogy.' He hinted that Sunshine's sequel would have featured 'an extraordinary idea' on 'kind of Elon Musk scale, even though he's lost a lot of credibility. But it was interplanetary stuff, it had more to do with that … there's no rich man in it. But the idea of looking outside and moving.' However, he wouldn't reveal more—out of respect to Garland, in case he ever wanted to repurpose the idea. Maybe Sunshine 2 might find life after all? Boyle's track record of long-delayed returns to his earlier films (28 Years Later, T2 Trainspotting) may give us hope yet.

Archaeologists in France Discover Giant Roman Gallic Villa Hiding in Plain Sight
Archaeologists in France Discover Giant Roman Gallic Villa Hiding in Plain Sight

Gizmodo

time3 hours ago

  • Gizmodo

Archaeologists in France Discover Giant Roman Gallic Villa Hiding in Plain Sight

A recent excavation reveals that a large building excavated in 1966 was just a part of an even grander ancient complex. In 1966, archaeologists in France uncovered an ancient 7,535-square-foot building near the town of Auxerre. Remains of furniture in the edifice's ten rooms led archaeologists to estimate that it was inhabited from the first to the fourth century CE, and evidence of mosaics and floor heating indicated that the inhabitants were members of a wealthy social class. But it turns out that these spaces were a small part of an even grander dwelling. Archaeologists have revealed that the building excavated almost six decades ago is just a secondary wing of a luxurious 43,056-square-foot villa—one of the largest known Roman villas in modern-day France. According to an agricultural treatise by the ancient Roman writer Lucius Junius Moderatus Columella called De Re Rvstica, Roman villas were divided into three main sections: the pars urbana, where the landowner and his family lived; the pars rustica, which housed the workers, animals, and farming tools; and the pars fructuaria for the harvest tools. The excavation near Auxerre has thus far revealed the complex's residential pars urbana, along with some features that may have belonged to the pars rustica. The building wrapped around a square garden, with a basin at one end and a fountain at the other. The chambers surrounding the garden included spaces to receive guests, technical rooms, and possible a kitchen, and the eastern wing of the building showcased thermal baths. The space that may have belonged to the pars rustica section of the complex consists of a rectangular space near a boundary wall that encircles part of the villa. In a statement by France's National Institute for Preventive Archaeological Research (Inrap), archaeologists suggest the villa was built in two or three stages. Further research will be necessary to determine the building's potential association with ancient Auxerre, known as Autessiodurum, which became a prominent city in the fourth century. By the mid first century BCE, future Roman dictator-for-life Julius Caesar had conquered all of Gaul, a region including most of modern day France and Belgium. Large Roman Gallic villas traditionally had richly developed pars urbana and almost always included private thermal baths. They also usually incorporated fountains, gardens, private sanctuaries, and elaborate interiors featuring marble, frescoes, and mosaics for the enjoyment of their wealthy landowners, who made up the region's political elite. The recently uncovered estate represents one of the largest Roman villas in Gaul, according to The History Blog. It remains to be seen what further insight the magnificent remains will provide into the lives of Gaul's wealthiest ancient residents. In the meantime, visitors will have the rare opportunity to tour the site on June 15 in honor of European Archaeology Days.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store